Nasdaq

Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer

Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United States SALT LAKE CITY, March 17 ...

New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

(NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces newly published data from the largest individual-patient-data meta-analysis of Prolaris to date, ...
Business Insider

Myriad Launches riskScore™ Beginning the Next Epoch in Hereditary Cancer TestingProvides Individualized Breast Cancer Risk for Patients Testing Negative with the myRisk ...

SALT LAKE CITY, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that it has launched riskScore ™, a ...
Hosted on MSN

Myriad expands hereditary cancer test to include additional genes

Myriad Genetics has broadened the scope of its MyRisk Hereditary Cancer Test for germline testing, adding genes cited in the NCCN Clinical Practice Guidelines in Oncology and those recommended by the ...
EurekAlert!

Myriad presents data on BRACAnalysis CDx and HRD at 2014 ASCO meeting

SALT LAKE CITY, Utah, May 30, 2014 – Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics, announced the presentation of new data at the American Society of Clinical Oncology ...